Flucloxacillin Hypersensitivity : Patient Outcomes in a Multicenter Retrospective Study
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Flucloxacillin is a narrow-spectrum, beta-lactamase-resistant penicillin. Type I (IgE-mediated) and type IV (T-cell-mediated) reactions are less frequently reported than with other penicillins.
OBJECTIVE: To undertake a detailed clinical characterization of a cohort of patients referred with suspected flucloxacillin hypersensitivity.
METHODS: We retrospectively analyzed demographic characteristics, presentation, investigation, and management of 108 patients presenting to 4 UK centers. Patients underwent skin prick and intradermal testing with flucloxacillin, major (benzylpenicilloyl poly-l-lysine) and minor determinants, amoxicillin, and benzylpenicillin with immediate and, where appropriate, delayed reading of the test. In the immediate group, a further 14 patients were tested to ampicillin and 16 to Augmentin (co-amoxiclav-combination of clavulanic acid and amoxicillin). Skin test-negative patients underwent oral drug provocation. A multistep protocol was used, depending on risk assessment.
RESULTS: Forty of 108 (37%) patients were diagnosed with hypersensitivity to flucloxacillin, of whom 33 (82.5%) showed immediate and 7 (17.5%) nonimmediate hypersensitivity, respectively. In the immediate group, most reactions were severe: 19 of 33 (58%). Intradermal testing had a higher negative predictive value (86%) in the immediate group than in the nonimmediate group (67%). Only a minority of patients (6 of 17 [35%]) with IgE-mediated allergy were cross-sensitized on intradermal testing with other penicillins, compared with 3 of 4 (75%) in the delayed group.
CONCLUSIONS: Immediate hypersensitivity reactions to flucloxacillin are more common than delayed. Cross-sensitization to other penicillins appears higher in delayed reactions than in immediate. The negative predictive value of intradermal testing is higher in the immediate group than in the nonimmediate group. Drug provocation testing remains the diagnostic criterion standard.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. In practice - 7(2019), 7 vom: 20. Sept., Seite 2212-2217.e1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kennard, Lucinda [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.09.2020 Date Revised 14.09.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaip.2019.03.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295451238 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295451238 | ||
| 003 | DE-627 | ||
| 005 | 20231225083703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaip.2019.03.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0984.xml |
| 035 | |a (DE-627)NLM295451238 | ||
| 035 | |a (NLM)30922988 | ||
| 035 | |a (PII)S2213-2198(19)30282-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kennard, Lucinda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Flucloxacillin Hypersensitivity |b Patient Outcomes in a Multicenter Retrospective Study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.09.2020 | ||
| 500 | |a Date Revised 14.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Flucloxacillin is a narrow-spectrum, beta-lactamase-resistant penicillin. Type I (IgE-mediated) and type IV (T-cell-mediated) reactions are less frequently reported than with other penicillins | ||
| 520 | |a OBJECTIVE: To undertake a detailed clinical characterization of a cohort of patients referred with suspected flucloxacillin hypersensitivity | ||
| 520 | |a METHODS: We retrospectively analyzed demographic characteristics, presentation, investigation, and management of 108 patients presenting to 4 UK centers. Patients underwent skin prick and intradermal testing with flucloxacillin, major (benzylpenicilloyl poly-l-lysine) and minor determinants, amoxicillin, and benzylpenicillin with immediate and, where appropriate, delayed reading of the test. In the immediate group, a further 14 patients were tested to ampicillin and 16 to Augmentin (co-amoxiclav-combination of clavulanic acid and amoxicillin). Skin test-negative patients underwent oral drug provocation. A multistep protocol was used, depending on risk assessment | ||
| 520 | |a RESULTS: Forty of 108 (37%) patients were diagnosed with hypersensitivity to flucloxacillin, of whom 33 (82.5%) showed immediate and 7 (17.5%) nonimmediate hypersensitivity, respectively. In the immediate group, most reactions were severe: 19 of 33 (58%). Intradermal testing had a higher negative predictive value (86%) in the immediate group than in the nonimmediate group (67%). Only a minority of patients (6 of 17 [35%]) with IgE-mediated allergy were cross-sensitized on intradermal testing with other penicillins, compared with 3 of 4 (75%) in the delayed group | ||
| 520 | |a CONCLUSIONS: Immediate hypersensitivity reactions to flucloxacillin are more common than delayed. Cross-sensitization to other penicillins appears higher in delayed reactions than in immediate. The negative predictive value of intradermal testing is higher in the immediate group than in the nonimmediate group. Drug provocation testing remains the diagnostic criterion standard | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Allergy | |
| 650 | 4 | |a Anaphylaxis | |
| 650 | 4 | |a Challenge | |
| 650 | 4 | |a Drug | |
| 650 | 4 | |a Flucloxacillin | |
| 650 | 4 | |a Intradermal test | |
| 650 | 4 | |a Isoxazoloyl | |
| 650 | 4 | |a Penicillin | |
| 650 | 4 | |a Skin prick test | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Immunoglobulin E |2 NLM | |
| 650 | 7 | |a 37341-29-0 |2 NLM | |
| 650 | 7 | |a Floxacillin |2 NLM | |
| 650 | 7 | |a 43B2M34G2V |2 NLM | |
| 650 | 7 | |a Amoxicillin-Potassium Clavulanate Combination |2 NLM | |
| 650 | 7 | |a 74469-00-4 |2 NLM | |
| 650 | 7 | |a Amoxicillin |2 NLM | |
| 650 | 7 | |a 804826J2HU |2 NLM | |
| 650 | 7 | |a Tryptases |2 NLM | |
| 650 | 7 | |a EC 3.4.21.59 |2 NLM | |
| 650 | 7 | |a Penicillin G |2 NLM | |
| 650 | 7 | |a Q42T66VG0C |2 NLM | |
| 700 | 1 | |a Rutkowski, Krzysztof |e verfasserin |4 aut | |
| 700 | 1 | |a Siew, Leonard Q C |e verfasserin |4 aut | |
| 700 | 1 | |a Nakonechna, Alla |e verfasserin |4 aut | |
| 700 | 1 | |a Sargur, Ravishankar |e verfasserin |4 aut | |
| 700 | 1 | |a Egner, William |e verfasserin |4 aut | |
| 700 | 1 | |a Shrimpton, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Mirakian, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Annette |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. In practice |d 2013 |g 7(2019), 7 vom: 20. Sept., Seite 2212-2217.e1 |w (DE-627)NLM227247523 |x 2213-2201 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2019 |g number:7 |g day:20 |g month:09 |g pages:2212-2217.e1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaip.2019.03.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2019 |e 7 |b 20 |c 09 |h 2212-2217.e1 | ||